Clinical Trial

A Study of Dengue Tetravalent Vaccine (TDV) in Adults (Age 45 to 60 and >60 to 79 Years)

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
Dengue fever is caused by an infection with the dengue virus. Vaccination with Dengue Tetravalent Vaccine (TDV) can help prevent dengue fever. Researchers have seen that dengue fever now also happens more often in elderly persons. The main aim of this study is to learn more about the side effects of TDV in adult (45 - 60 years) and elderly (60 - 79 years) persons and about TDV's ability to create an immune response in adult and elderly persons. Another aim is to learn about the side effects of TDV in adult and elderly persons in endemic countries who have one or more additional medical conditions (called comorbidities) such as diabetes mellitus, hypertension or a chronic kidney condition. In this study, participants will receive 2 vaccinations with TDV (the second 3 months after the first). During the study, participants will visit their study clinic 5 times.
Trial Details
NCT Number NCT06579755
Lead Sponsor Takeda
Conditions Dengue Fever
Enrollment 800 participants
Start Date 2026-01-20
Primary Completion 2027-04-14 (estimated)
Study Completion 2027-04-14 (estimated)
Updated on ClinicalTrials.gov 2026-04-29